Indeed, research has shown that conjugation of HER2-derived epitope peptides to an antigenic carrier can induce antibodies that recognize HER2 expressed on tumor cells [1,2,20]; and several anti-HER2 peptide vaccines, such as E75 [21], GP2 [22], and AE37 [23] formulations have advanced into clinical testing. This evidence concerns the gene ERBB2 and neoplasm.